爱硒健康,提供乳腺癌、肺癌等癌症康复前期预防及后期癌症康复计划

2021 ESMO中国学者口头报告名单火热出炉!18项研究成功入围

转发文章到朋友圈,扫描二维码或微信623296388,截屏给硒教授,赠癌症食疗电子书

*仅供医学专业人士阅读参考

它来了它来了!

欧洲最负盛名和最具影响力的肿瘤学会议——欧洲肿瘤内科学会(ESMO)年会将在9月如约而至,本次大会时间为9月16日-9月21日(中欧夏令时)。

医学界肿瘤频道小编整理了口头报告专场(Proffered Paper session)以及mini口头报告专场(mini oral session)的中国讲者报告主题。话不多说,让我们看看2021 ESMO年会,有哪些值得关注的“中国之声”呢?(以下排名不分先后,如有遗漏敬请谅解,欢迎留言补充)

消化道肿瘤

1.专场:mini oral session-Gastrointestinal tumours, non-colorectal

摘要号:LBA52

题目:信迪利单抗联合化疗对比化疗一线治疗晚期或转移性食管鳞癌:Ⅲ期ORIENT-15研究的首次结果

Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First Results of the Phase 3 ORIENT-15 study

报告者:北京大学肿瘤医院 沈琳教授

2.专场:mini oral session-Gastrointestinal tumours, non-colorectal

摘要号:LBA53

题目:信迪利单抗联合化疗对比化疗一线治疗晚期胃或胃食管交界(G/GEJ)腺癌(ORIENT-16):一项随机、双盲、Ⅲ期研究的首次结果

Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase 3 study

报告者:解放军总医院第五医学中心 徐建明教授

3.专场:mini oral session-Gastrointestinal tumours, non-colorectal

摘要号:1373MO

题目:JUPITER-06:特瑞普利单抗与安慰剂联合一线化疗治疗初治晚期或转移性食管鳞癌(ESCC)的随机、双盲、Ⅲ期研究

JUPITER-06: A Randomized, Double-blind, Phase 3 Study of Toripalimab versus Placebo In Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

报告者:中山大学肿瘤防治中心 徐瑞华教授

4.专场:Proffered Paper session – Gastrointestinal tumours, non-colorectal

摘要号:1372O

题目:消化系统肿瘤患者的CLDN 18.2靶向CAR-T细胞治疗

CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system

报告者:北京大学肿瘤医院 齐长松医生

5.专场:Proffered Paper session – Gastrointestinal tumours, colorectal 2

摘要号:LBA22

题目:奥沙利铂加卡培他滨新辅助化疗对比卡培他滨放化疗治疗无直肠系膜筋膜浸润的局部进展期直肠癌(CONVERT研究):一项多中心随机、开放标签Ⅲ期临床试验的初步结果

Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine Versus Chemoradiation with Capecitabine for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of A Multicenter Randomised, Open-label, Phase III Trial

讲者:中山大学肿瘤防治中心 丁培荣

乳腺癌

6.专场:mini oral session-Breast cancer, metastatic

摘要号:228MO

题目:PALOMA-4:哌柏西利(PAL)+来曲唑(LET)对比安慰剂(PBO)+LET治疗雌激素受体阳性/人类表皮生长因子受体2阴性(ER+/HER2-)晚期乳腺癌(ABC)的亚洲绝经后妇女的Ⅲ期试验主要结果

PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)

报告者:中国医学科学院肿瘤医院 徐兵河教授

肺癌

7.专场:Proffered Paper session – NSCLC, metastatic 2

摘要号:LBA48

题目:DUBLIN-3-3(BPI-2358-103):普那布林/多西他赛(Plin/Doc)联合与Doc在铂类化疗方案经治的EGFR野生型(wt)的二线/三线非小细胞肺癌(NSCLC)患者中进行的一项全球性Ⅲ期临床试验

DUBLIN-3(BPI-2358-103): A Global Phase (Ph) 3 Trial with the Plinabulin/Docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC Patients (pts) with EGFR-wild type (wt) Progressing on a Prior Platinum-Based Regimen

报告者:上海市胸科医院 韩宝惠教授

8.专场:Mini oral session – Non-metastatic NSCLC and other thoracic malignancies

摘要号:LBA43

题目:GEMSTONE-301:舒格利单抗治疗同步或序贯放化疗(CRT)后未进展、不能切除的III期NSCLC患者的一项随机、双盲、安慰剂对照的Ⅲ期研究

GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase 3 study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC)who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

报告者:广东省人民医院 吴一龙教授

血液恶性肿瘤

9.专场:Proffered Paper session – Haematological malignancies

摘要号:825O

题目:Ivosidenib在伴有IDH1突变的复发/难治性急性髓系白血病(R/R AML)中国患者中的应用:一项桥接注册研究的结果

Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: results from a bridging registrational study

报告者:Mingyuan Sun (Tianjin, China)

10.专场:Mini oral session – Haematological malignancies

摘要号:828MO

题目:原发性胃肠道弥漫性大B细胞淋巴瘤的外显子突变谱

Exonic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

报告者:中山大学附属第六医院 李珊珊医生

11.专场:Mini oral session – Haematological malignancies

摘要号:830MO

题目:中国NK/T细胞淋巴瘤患者的整合驱动突变谱

Integrated Driver Mutations Profile of Chinese NK/T Cell Lymphoma

报告者:Ting-zhi Liu (Guangzhou, China)

12.专场:Mini oral session – Haematological malignancies

摘要号:831MO

题目:杰诺单抗在中国复发或难治性原发性纵隔大B细胞淋巴瘤患者中的应用:一项多中心、开放标签、单臂II期试验结果

Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial

报告者:中国医学科学院肿瘤医院 石远凯教授

13.专场:Mini oral session – Haematological malignancies

摘要号:833MO

题目:PI3Kδ抑制剂HMPL-689在中国复发/难治性淋巴瘤患者中的Ⅰb期研究结果

A phase1b study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma

报告者:复旦大学附属肿瘤医院 曹军宁教授

头颈部肿瘤

14.专场:Proffered Paper session – Head and neck cancer, excl. Thyroid

摘要号:858O

题目:KEYNOTE-122的结果:帕博利珠单抗(pembro)单药治疗与化疗(chemo)治疗铂类预处理、复发或转移(R/M)鼻咽癌(NPC)的Ⅲ期研究

Results of KEYNOTE-122: a phase 3 study of pembrolizumab(pembro) monotherapy vs chemotherapy(chemo)for platinum-pretreated, recurrent or metastatic(R/M)nasopharyngeal carcinoma(NPC)

报告者:威尔士亲王医院(Prince of Wales Hospital) 陈德彰教授

15.专场:Proffered Paper session – Head and neck cancer, excl. Thyroid

摘要号:859O

题目:改进EB病毒相关鼻咽癌TNM分期系统:一项多中心队列研究

Refining TNM Staging System for Epstein-Barr Virus-Related Nasopharyngeal Carcinoma: A Multicenter Cohort Study

报告者:Wang-Zhong Li (Guangzhou, China)

支持性与姑息性治疗

16.专场:Mini oral session – Supportive and palliative care

摘要号:LBA64

题目:奥氮平,地塞米松的替代品用于预防基于顺铂的双重高致吐性化疗引起的恶心和呕吐:一项非劣效性、前瞻性、多中心、随机、对照的Ⅲ期临床试验

Olanzapine, an Alternative to Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-Based Doublet Highly Emetogenic Chemotherapy: A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase 3 Clinical Trial

报告者:中山大学附属第五医院 刘志刚教授

基础研究

17.专场:Mini oral session – Basic science

摘要号:4MO

题目:新型CDK4/6抑制剂GLR2007在乳腺癌和肺癌模型中的临床前评价

Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models

报告者:Lei Yin (Beijing, China)

18.专场:Proffered Paper session – Basic science

摘要号:2O

标题:Penpulimab,一种具有Fc改造功能以消除效应功能和具有独特效应表位和结合特性的IgG1抗PD-1抗体

Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties

Penpulimab,一种具有Fc改造功能以消除效应功能和具有独特效应表位和结合特性的IgG1抗PD-1抗体

报告者:Baiyong Li(Zhongshan,China)

参考来源:

https://www.esmo.org/meetings/esmo-congress-2021/programm

– End –

加硒教授微信:623296388,送食疗电子书,任选一本

本文来自互联网,若有版权问题,请联系编辑及时删除。癌症康复-广东爱硒健康管理有限公司官网 » 2021 ESMO中国学者口头报告名单火热出炉!18项研究成功入围

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址

提供乳腺癌、肺癌等癌症康复前期预防及后期癌症康复计划

联系我们硒教授微信:623296388